Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03441100 · ClinicalTrials.gov registry record · Phase 1
TCR-engineered T Cells in Solid Tumors: IMA202-101
A Phase 1 study, sponsored by Immatics US.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03441100 is a Phase 1 study that has completed, run by Immatics US. The registered enrollment target is 16 participants.
The verdict
NCT03441100, a Phase 1 study, has completed, sponsored by Immatics US.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The study purpose is to establish the safety and tolerability of IMA202 product in patients with solid tumors that express melanoma-associated antigen 1 (MAGEA1).
Interventions
- DEVICE IMADetect®
- DRUG IMA202 Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-05-02 |
| Est. Completion | 2023-03-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03441100
The ClinicalTrials.gov registry entry for NCT03441100 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immatics US, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IMADetect® is the first listed.
NCT03441100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03441100 about?
NCT03441100 is a clinical study titled "TCR-engineered T Cells in Solid Tumors: IMA202-101". The study purpose is to establish the safety and tolerability of IMA202 product in patients with solid tumors that express melanoma-associated antigen 1 (MAGEA1).
What is the current status of trial NCT03441100?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2019-05-02. Estimated completion is 2023-03-17.
What interventions are being tested in trial NCT03441100?
The interventions under investigation include: IMADetect® (DEVICE), IMA202 Product (DRUG).
Who is sponsoring clinical trial NCT03441100?
This trial is sponsored by Immatics US, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.